Silence Therapeutics Plc has promoted Marie Wikström Lindholm to its executive leadership team to oversee the molecular design of the company’s short interfering ribonucleic acid (siRNA) therapeutics. Dr Lindholm joined the company in 2017 and has been head of technology. She has more than 13 years of experience with oligonucleotide therapeutics starting with Santaris Pharma A/S in Denmark. When Santaris was acquired by Roche in 2014, she then transferred to the Roche Innovation Center in Copenhagen.
Dr Lindholm holds a PhD from Uppsala University in Sweden and worked as an academic before joining industry.
Silence Therapeutics announced the appointment on 2 November 2020
Copyright 2020 Evernow Publishing Ltd